Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — Investor Presentation (September 2026)
16 slides from Clever Culture Systems's investor presentation, September 2026
Slide 1: AI-powered microbiology
ASX: CC5 AI- powered microbiology Revolutionising microbial quality control in pharmaceutical manufacturing Brent Barnes, CEO and Managing Director September 2026 Clever Culture Systems ASX: CC5 1
Slide 2: Forward-looking statements and disclaimer
This document contains certain forward - looking statements that involve risks and uncertainties. Although we believe that the exp ectations reflected in the forward - looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Given the
Slide 3: Context: sterile drug manufacturing
Context: sterile drug manufacturing Clever Culture Systems. ASX: CC5 3
Slide 4: Environmental monitoring today
Workflow Environmental monitoring today Mandatory process in every pharmaceutical manufacturing facility globally Environmental Culture plates monitoring Critical decision point Culture plate reading, reporting. Result to release pharmaceutical product Cleanrooms No Growth (pharmaceutical manufactur
Slide 5: Sterility failures are catastrophic – 2023 case study
Patient safety Sterility failures are catastrophic – 2023 case study Validated sterility control systems matter. Environmental monitoring is one critical layer that detects microbial contamination before it reaches patients US FDA observation: “ manufacturing process that lacked assurance of product
Slide 6: Digital disruption Solution: APAS
Solution Digital disruption Solution: APAS Automated Plate Assessment System Cutting edge AI technology Machine learning for microbiology applications Demonstrated performance Extensive scientific data, faster than microbiologist Improved data integrity Automatic data trails and audit reports Easy i
Slide 7: In drug manufacturing (GMP), proof is validated performance
AI built for GMP In drug manufacturing (GMP), proof is validated performance APAS is built by microbiologists, for microbiologists. 10+ years of knowledge to design, execute and provide the evidence that APAS algorithms work to GMP standards High regulatory standards are required and applied to auto
Slide 8: Up to AU$1.2m revenue per APAS Independence sale
Revenue Up to AU$1.2m revenue per APAS Independence sale 1 Includes up - front Capex and Annual Recurring Revenue (ARR) streams Product / Approx. Description Revenue Model Service Split APAS ® Upfront Capex Laboratory (inc. financing 40% Independence Instrumentation options) APAS Apps ® AI Software
Slide 9: Global footprint: 37 APAS Independence instruments
Global footprint: 37 APAS ® Independence instruments Asia - Pac: 7 instruments USA: 11 instruments Europe: 19 instruments Global pharma customer focus: AstraZeneca, Bristol Myers Squibb, Pfizer, Novo Nordisk, Patheon (Thermo Fisher), CSL APAS sales APAS Training Hub Clever Culture Systems ASX: CC5 9
Slide 10: Targeting the highest value 50% of the market
Targeted opportunity Targeting the highest value 50% of the market The most value to gain in an already large total addressable market Attractive market: APAS Independence addresses the largest • Highest testing volumes manufacturers: ~50% of the global opportunity: • Greatest economic return • Larg
Slide 11: Total addressable pharmaceutical market – $2.8B
Opportunity Total addressable pharmaceutical market – $2.8B Market Opportunity – sterile pharmaceutical manufacturing Market CAGR growth >8% 58% Annual SaaS Opportunity $1.6B $1.2B SaaS / ARR Up - front CAPEX Recurring $230M ARR Annual AI software license + hardware Instrument hardware maintenance o
Slide 12: Land & Expand playbook: FY25 + FY26 foundation set
Tipping point for CC5 Land & Expand playbook: FY25 + FY26 foundation set How it works Landed 8 global pharmaceutical customers LAND AstraZeneca Novo Nordisk - Expand 1 1- 2 instruments at a global 12 instruments – global sites 3 instruments, validation started pharma site Bristol Myers Squibb Pfizer
Slide 13: AstraZeneca Case Study
Customer AstraZeneca Case Study Enterprise customer – Standardisation across multiple global sites 12 instruments • ~1,000 plates per day at large AZ sites purchased and installed • >98% of plates are negative • Occasionally humans make mistakes • Multiple global • APAS resolves data integrity chall
Slide 14: Board and Management
Experienced Board and Management Focused on expansion into pharmaceutical manufacturing industry • Board and Management shareholding 20%+ Brent Barnes Rebecca Wilson CEO and MD, AU Chair, AU Aug - 16 start Jul - 23 start • International experience with healthcare, technology and pharmaceutical manuf
Slide 15: FY27: the tipping point begins
Tipping point for CC5 FY27: the tipping point begins Growth increasingly comes from inside the accounts we've already won ✓ Step change increase in sales Targeting a near - term qualified sales FY27 is where land & expand starts compounding into sales growth pipeline of 180 instruments ✓ Growing Saa
Slide 16: Thank you
Thank you Clever Culture Systems. ASX: CC5 16
Clever Culture Systems — Investor Presentation (September 2026) on 6ix